Investment Objective
|
The investment objective of the scheme is to seek long term capital appreciation by investing in equity/equity related instruments of
companies from the healthcare sector. However, there is no assurance or guarantee that the investment objective of the Scheme will be
achieved. The Scheme does not assure or guarantee any returns.
|
Category of Scheme
|
Thematic
|
Type of Scheme
|
An open ended equity scheme predominantly investing in large cap stocks
|
Inception Date
|
17-Jul-23
|
Lock in Period
|
Nil
|
Minimum Application Amount
|
For new investor, INR 5000/- and any amount thereafter
For existing investors, INR 1000/- and any amount thereafter
For Systematic Investment Plan (SIP), the minimum amount is INR 1000/- and in multiples of INR 1/- thereafter.
|
Benchmark Index
|
S&P BSE Healthcare TRI
|
Load Structure
|
Entry Load - Nil
Exit Load -15 Days / 1% Effective From August 11,2023
|
Asset Allocation Pattern
|
Under normal circumstances, the asset allocation pattern will be as follows
|
Indicative allocations (% of total assets)
|
Risk Profile
|
Instrument
|
Minimum
|
Maximum
|
High/Medium/Low
|
Equity and Equity related instruments in Healthcare space
|
80
|
100
|
Very High
|
Equity and equity related instruments other than Healthcare space
|
0
|
20
|
Very High
|
Foreign securities including ADRs / GDRs / Foreign equity and debt securities and Overseas ETFs 0 20 Very High Debt & Money Market instrument
|
0
|
20
|
Very High
|
Debt & Money Market instruments*
|
0
|
20
|
Low to Medium
|
Units issued by REITs & InvITs
|
0
|
5
|
Very High
|
The Scheme does not intend to invest in securities with Structured Obligations or Credit Enhancements. The Scheme does not intend
to invest in debt instruments with special features in line with SEBI Circular no. SEBI/HO/IMD/DF4/CIR/P/2021/032 dated March 10,2021
* In line with SEBI Circular dated November 29, 2022, the scheme shall not invest more than:a. 10% of its NAV in debt and money market securities rated AAA;
b. 8% of its NAV in debt and money market securities rated AA;
c. 6% of its NAV in debt and money market securities rated A and below: issued by a single issuer.
The above investment limits may be extended by up to 2% of the NAV of the scheme with prior approval of the Board of Trustees and
Board of Directors of the AMC, subject to compliance with the overall 12% limit specified in clause 1 of Seventh Schedule of SEBI MFRegulation.
The investment pattern stated above is indicative and may be changed due to market conditions. The proportion of the scheme
invested in each type of security will vary in accordance with microeconomic & macroeconomic conditions, interest rates, and other
relevant considerations. These instances may be beyond the control of the fund manager & the AMC and hence may require such
deviations. Such changes in the investment pattern will be transitionary in nature and will be undertaken as defensive considerations
only in accordance with SEBI circular dated March 04, 2021. Defensive considerations may be determined by the fund manager and in
case of deviations on account of exogenous factors, the fund manager will endeavor to rebalance the Scheme within 30 calendar days
from the date of such deviation. The intention being at all times to seek to protect the interests of the Unit holders. The risks associated
with each investment are an important factor as well. The net assets of this scheme shall predominantly be invested as per the
investment pattern stated above.
|
Fund Manager
|
Mr. Sandeep Tandon, Mr. Ankit Pande, Mr. Sanjeev Sharma, Mr. Vasav Sahgal
|
Plans Available
|
Regular Plan and Direct Plan.
(The Regular and Direct plan will have a common portfolio)
|
Options Available
|
1. Growth Option and 2. IDCW
The IDCW option has the following facilities: (i) IDCW Reinvestment Facility. (ii) IDCW Pay-out Facility. Default Investment option is Growth Option. For the IDCW option, the default facility will be IDCW Reinvestment.
|
Applicable NAV
|
The NAV applicable for purchase or redemption or switching of Units based on the time of the Business Day on which the application is time stamped
|
Risk Factors
|
For detailed scheme/securities related risk factors, please refer to the Scheme Information Document
|
Investment Strategy
|
The scheme will invest at least 80% in healthcare, life sciences,
insurance and wellness companies that are expected to benefit
from increased investments in healthcare infrastructure and
service delivery, including advanced medical technology. These
include pharmaceuticals, biotech, hospitals, medical devices,
diagnostic services, clinical trials, outsourcing, telemedicine, medical
tourism, health insurance, medical equipment, MedTech etc.
Flexibility to invest in companies, across market caps, to optimize riskreturn payoffs
Being inflexion point strategists, our money managers will construct a
focused or diversified portfolio, based on the sub-sector outlook
VLRT, our risk mitigating investment framework, and Predictive
Analytics tools will be used to dynamically manage the known risks
and identifying opportunities across the portfolio
|
Statutory Details: Sponsor: quant Capital Finance & Investments Private Limited
Investment Manager:quant Money Managers Limited. CIN: U74899MH1995PLC324387
|